TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31023428

Group type: EXPERIMENTAL
Intervention: Control of 6 or 7 risk factors
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Control of 3 to 7 risk factors
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: No smoking, regular physical activity, dietary adherence, A1c <7%
Number of subjects: 690

Group type: COMPARATOR
Intervention: 0 to 1 controlled risk factors
Number of subjects: 690
Study: 28867497

Group type: EXPERIMENTAL
Intervention: Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg
Number of subjects: 631

Group type: COMPARATOR
Intervention: Dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Bictegravir, emtricitabine, and tenofovir alafenamide
Number of subjects: 631

Group type: COMPARATOR
Intervention: Dolutegravir, abacavir, and lamivudine
Number of subjects: 631
Study: 25487355

Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV) added to peginterferon and ribavirin (PR)
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Placebo (PBO) added to peginterferon and ribavirin (PR)
Number of subjects: 1161
Study: 24245929

Group type: EXPERIMENTAL
Intervention: mTBI without LOC (n = 53)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: mTBI with LOC (n = 35)
Number of subjects: 127

Group type: COMPARATOR
Intervention: no-TBI (n = 39)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: PTSD and depression symptoms
Number of subjects: 127
Study: 23038220

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (Dar), cumulative dose 11.1 µg/kg b.w. over 8 months
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (Co)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (Dar)
Number of subjects: 63
Study: 19239712

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 984

Group type: COMPARATOR
Intervention: Vaginal placebo
Number of subjects: 984
Study: 17519150

Group type: EXPERIMENTAL
Intervention: Extended oral contraceptive regimen containing 3 mg drosperinone and 30 microg ethinyl estradiol
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 3-day hormone-free interval (HFI)
Number of subjects: 111

Group type: COMPARATOR
Intervention: 21/7 cycle
Number of subjects: 111
Study: 15593360

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 342
Study: 12414848

Group type: EXPERIMENTAL
Intervention: Continuous treatment with daily injections of 0.4 mg GH/d (group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intermittent treatment with 0.8 mg GH/d for 14 days every 3 months (group B)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both treatment groups (A and B)
Number of subjects: 29
Study: 9884268

Group type: EXPERIMENTAL
Intervention: TNFR:Fc 1 hr before OKT3 on days 0 and 3
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TNFR:Fc
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no TNFR:Fc)
Number of subjects: 16
Study: 8681976

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of aminoglycosides
Number of subjects: 3181
Study: 1695801

Group type: EXPERIMENTAL
Intervention: Chemotherapy group (89 patients) received Vincristine (1.5 mg/m2), Bleomycin (15 mg), Methotrexate (80 mg)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (98 patients) underwent the same surgical procedure
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Both groups (chemotherapy and control)
Number of subjects: 226
Study: 356761

Group type: EXPERIMENTAL
Intervention: Intermittent levamisole therapy (150 mg daily for 3 days of each week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous levamisole therapy (150 mg daily)
Number of subjects: 0
Study: 31761933

Group type: EXPERIMENTAL
Intervention: Empiric TB treatment
Number of subjects: 850

Group type: COMPARATOR
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 850
Study: 30602450

Group type: EXPERIMENTAL
Intervention: Dynamic altering stimuli (DAS) video viewing for 30 minutes using ReviView
Number of subjects: 35
Study: 26776321

Group type: EXPERIMENTAL
Intervention: Biopsychosocial evidence-based booklet
Number of subjects: 129

Group type: COMPARATOR
Intervention: Biomedical-based booklet (Control)
Number of subjects: 129
Study: 25940331

Group type: EXPERIMENTAL
Intervention: Tetraspan™ 10 mL kg⁻¹ for preloading and 0.9% saline for maintenance until six hours from the end of preloading
Number of subjects: 160

Group type: COMPARATOR
Intervention: 0.9% saline for preloading and maintenance until six hours from the end of preloading
Number of subjects: 160
Study: 23054528

Group type: EXPERIMENTAL
Intervention: Supplemental video educational program
Number of subjects: 474

Group type: COMPARATOR
Intervention: Traditional lecture series (Control)
Number of subjects: 474
Study: 22055892

Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS)
Number of subjects: 110
Study: 19377050

Group type: EXPERIMENTAL
Intervention: Epidural neostigmine 4 microg/mL with bupivacaine 1.25 mg/mL by patient-controlled epidural analgesia
Number of subjects: 52

Group type: COMPARATOR
Intervention: Bupivacaine 1.25 mg/mL alone
Number of subjects: 52
Study: 16342193

Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF, 5 microg/kg/day) administered subcutaneously for 5 days for mobilization of CD34(+) cells.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Collection of peripheral blood progenitor cells (PBPCs) on day 5 after G‐CSF administration.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: G‐CSF mobilization of CD34(+) cells.
Number of subjects: 9
Study: 15515749

Group type: EXPERIMENTAL
Intervention: Three‐phase bone scintigraphy using Tc‐99m‐MDP
Number of subjects: 32
Study: 10542895

Group type: EXPERIMENTAL
Intervention: 500 ml 6% HES 200/0.62 (30 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 ml 10% HES 200/0.5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HES 200/0.62
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HES 200/0.5
Number of subjects: 0
Study: 7498231

Group type: EXPERIMENTAL
Intervention: [123I]beta‐CIT‐FE
Number of subjects: 4

Group type: COMPARATOR
Intervention: [123I]beta‐CIT
Number of subjects: 4

Group type: COMPARATOR
Intervention: [123I]beta‐CIT‐FP
Number of subjects: 4
Study: 2312773

Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol CR/ZOK
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7010383

Group type: EXPERIMENTAL
Intervention: 250 mg cefaclor 3‐times daily (intermittent)
Number of subjects: 298

Group type: COMPARATOR
Intervention: 500 mg amoxycillin 3‐times daily (continuous)
Number of subjects: 298
Study: 31525129

Group type: EXPERIMENTAL
Intervention: Raw almonds (1.5 oz twice daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: CHO-based foods (isocaloric)
Number of subjects: 33
Study: 30896743

Group type: EXPERIMENTAL
Intervention: Calcium intake (mean 886 mg/day)
Number of subjects: 1994

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 1994
Study: 27400927

Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Benzodiazepine withdrawal (both groups)
Number of subjects: 80
Study: 25119374

Group type: EXPERIMENTAL
Intervention: Internet-based self-management intervention with interactive sections (8 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (denied access to interactive sections)
Number of subjects: 51
Study: 23164097

Group type: EXPERIMENTAL
Intervention: PTFE-covered balloon-expandable stents
Number of subjects: 174

Group type: COMPARATOR
Intervention: Uncovered balloon-expandable stents
Number of subjects: 174
Study: 19879131

Group type: EXPERIMENTAL
Intervention: Radiotherapy and Tamoxifen for 2 years
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Radiotherapy only
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Tamoxifen only
Number of subjects: 347

Group type: COMPARATOR
Intervention: BCS only (Control)
Number of subjects: 347
Study: 17964983

Group type: EXPERIMENTAL
Intervention: Dworak grade 2 MDC (n = 19)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Dworak grade 1 MDC (n = 37)
Number of subjects: 56
Study: 15494457

Group type: EXPERIMENTAL
Intervention: GnRH (gonadotropin-releasing hormone) bolus iv injection
Number of subjects: 31
Study: 12194665

Group type: EXPERIMENTAL
Intervention: 3M APC Mini Twin bracket system
Number of subjects: 29

Group type: COMPARATOR
Intervention: Transbond XT adhesive
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Inexperienced operators
Number of subjects: 29
Study: 10455843

Group type: EXPERIMENTAL
Intervention: Buscopan 20 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 45
Study: 7598238

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac tromethamine (KT) 60 mg IV 15 min after skin incision
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo i.v.
Number of subjects: 30
Study: 2193555

Group type: EXPERIMENTAL
Intervention: 1-methadone (0.573 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1-methadone (1.145 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1-methadone (0.573 mg) + metamizol (50 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PCA (Patient-Controlled Analgesia)
Number of subjects: 120
Study: 7364735

Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 38
Study: 30614717

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1246
Study: 27801596

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) autoinjector
Number of subjects: 152

Group type: COMPARATOR
Intervention: Adalimumab, etanercept, and golimumab devices
Number of subjects: 152
Study: 25366527

Group type: EXPERIMENTAL
Intervention: Standing on a tilt table for 30 minutes per session, five times per week for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Not standing for 10 weeks followed by standing for 6 weeks
Number of subjects: 20
Study: 23843569

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (10 sessions, 3 sessions/week) on traditional Chinese acupoints
Number of subjects: 50
Study: 21690627

Group type: EXPERIMENTAL
Intervention: abacavir-lamivudine (ABC-3TC)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: tenofovir DF-emtricitabine (TDF-FTC)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: atazanavir-ritonavir (ATV-r)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: VAT:TAT
Number of subjects: 269
Study: 19533128

Group type: EXPERIMENTAL
Intervention: Corrective surgery for biliary atresia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liver transplantation when necessary
Number of subjects: 0
Study: 17162046

Group type: EXPERIMENTAL
Intervention: Intravesical atropine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Oral oxybutynin
Number of subjects: 57
Study: 16211594

Group type: EXPERIMENTAL
Intervention: Pergolide (3.23 mg/day)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Levodopa (504 mg/day)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 294

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 294
Study: 15570147

Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin solution (CHO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water (PLA)
Number of subjects: 9
Study: 11018576

Group type: EXPERIMENTAL
Intervention: Behavior change interventions, specific details not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaborative practitioner-participant relationship, specific details not available.
Number of subjects: 0
Study: 8872730

Group type: EXPERIMENTAL
Intervention: Use of image enhancement system during lithotripsy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard lithotripsy treatment without image enhancement
Number of subjects: 81
Study: 2053765

Group type: EXPERIMENTAL
Intervention: 360 mg sustained release verapamil as a single dose
Number of subjects: 18

Group type: COMPARATOR
Intervention: 360 mg sustained release verapamil as two divided doses
Number of subjects: 18
Study: 6352209

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pulsed intermittent subcutaneous insulin infusion (30‐, 60‐, and 120‐min intervals)
Number of subjects: 6
Study: 30080693

Group type: EXPERIMENTAL
Intervention: Nightly replacement (NR) of lenses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morning replacement (MR) of lenses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instillation of prophylactic antibiotic drops (AB) each morning/evening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily lens cleaning (LC) each morning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (combined data)
Number of subjects: 0
Study: 29072017

Group type: EXPERIMENTAL
Intervention: Acupuncture at thirteen evil acupoints
Number of subjects: 74

Group type: COMPARATOR
Intervention: Western medicine (intravenous injection of aspartate ornithine and branched chain amino acids)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 74
Study: 26019142

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1772

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1772
Study: 23867908

Group type: EXPERIMENTAL
Intervention: Pericardiocentesis and extended pericardial drainage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pericardiocentesis alone
Number of subjects: 0
Study: 22098306

Group type: EXPERIMENTAL
Intervention: Active pushing for 15-29 min (n=6589)
Number of subjects: 36832

Group type: EXPERIMENTAL
Intervention: Cord artery pH <7.00
Number of subjects: 36832

Group type: EXPERIMENTAL
Intervention: Active pushing duration
Number of subjects: 36832
Study: 19401125

Group type: EXPERIMENTAL
Intervention: Home-based intervention
Number of subjects: 283

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 283
Study: 17712034

Group type: EXPERIMENTAL
Intervention: Flexitouch (FT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lympha Press (LP)
Number of subjects: 10
Study: 14697480

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 340
Study: 11477242

Group type: EXPERIMENTAL
Intervention: Imaging (MR imaging or CT)
Number of subjects: 145

Group type: COMPARATOR
Intervention: No imaging
Number of subjects: 145
Study: 9537455

Group type: EXPERIMENTAL
Intervention: 15 microg of consensus interferon administered subcutaneously three times a week for 48 weeks
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: 15 microg of consensus interferon administered subcutaneously three times a week for 24 weeks
Number of subjects: 337
Study: 7819467

Group type: EXPERIMENTAL
Intervention: Atropine 2 micrograms/kg administered in 60 sec. intervals up to a total dose of 10 micrograms/kg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified how many patients)
Number of subjects: 31
Study: 2458264

Group type: EXPERIMENTAL
Intervention: Infusion of trypsin (150 mg h‐1; 1.25 g l‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion of aprotinin (1.5 X 10(6) KIU for 30 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion of trypsin (300 mg h‐1; 2.5 g l‐1)
Number of subjects: 0
Study: 30668199

Group type: EXPERIMENTAL
Intervention: EH301
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 28486033

Group type: EXPERIMENTAL
Intervention: Parent Management Training Oregon Model
Number of subjects: 0
Study: 25912296

Group type: EXPERIMENTAL
Intervention: Active rTMS (1‐Hz; 30 min; 1800 pulses per day for 3 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham rTMS (same duration and frequency as active rTMS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Open label active rTMS (after initial 3 weeks of active rTMS)
Number of subjects: 20
Study: 23589190

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) 20 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 21389180

Group type: EXPERIMENTAL
Intervention: High-protein and moderate-carbohydrate diet (HPMC; 139 g protein, 82 g fat, 181 g carbohydrate/d)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-protein and low-carbohydrate diet (HPLC; 137 g protein, 143 g fat, 22 g carbohydrate/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Weight-maintenance diet (85 g protein, 116 g fat, 360 g carbohydrate/d)
Number of subjects: 17
Study: 19730207

Group type: EXPERIMENTAL
Intervention: TDR-C (ProDisc-C, Synthes Spine)
Number of subjects: 180

Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: TDR-C and ACDF
Number of subjects: 180
Study: 17410010

Group type: EXPERIMENTAL
Intervention: Dose intensified chemotherapy (ICT) with filgrastim-supported sequential reinfusion of peripheral blood progenitor cells every 14 days
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard ICE chemotherapy (SCT) every 28 days
Number of subjects: 83
Study: 15285973

Group type: EXPERIMENTAL
Intervention: Integrated care (mental health and substance abuse providers co-located in primary care; N=999)
Number of subjects: 2022

Group type: COMPARATOR
Intervention: Enhanced referral to specialty mental health/substance abuse clinics (N=1,023)
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 2022

Group type: COMPARATOR
Intervention: Enhanced referral
Number of subjects: 2022

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 2022
Study: 11849198

Group type: EXPERIMENTAL
Intervention: SJW (0.15%) 600 mg three times daily for 16 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9990574

Group type: EXPERIMENTAL
Intervention: Glutamine-containing enteral feed
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control feed (isonitrogenous, isoenergetic)
Number of subjects: 78
Study: 7774533

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (n = 5)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sunflowerseed oil (n = 6)
Number of subjects: 11
Study: 2185350

Group type: EXPERIMENTAL
Intervention: Treatment of risk factors (specific interventions not detailed)
Number of subjects: 0
Study: 463804

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (65% of total energy)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (45% of total energy)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucrose-containing diets (45% of total energy)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucrose-containing diets (65% of total energy)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Corn syrup diets (45% of total energy)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Corn syrup diets (65% of total energy)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diet-induced changes in fasting or integrated plasma cholesterol concentration
Number of subjects: 8
Study: 31880006

Group type: EXPERIMENTAL
Intervention: ixazomib
Number of subjects: 637

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 637
Study: 31533105

Group type: EXPERIMENTAL
Intervention: Peach tree pollen (PTP) sensitisation
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Prunus persica 9 (Pru p 9) sensitisation
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Nasal provocation test (NPT)
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Symptoms (rhinitis or rhinoconjunctivitis)
Number of subjects: 685
Study: 26828264

Group type: EXPERIMENTAL
Intervention: Moderate-intensity treadmill walking
Number of subjects: 24

Group type: COMPARATOR
Intervention: Light-intensity treadmill walking
Number of subjects: 24

Group type: COMPARATOR
Intervention: High-intensity treadmill walking
Number of subjects: 24

Group type: COMPARATOR
Intervention: Seated quiet rest
Number of subjects: 24
Study: 24918473

Group type: EXPERIMENTAL
Intervention: painACTION.com (online pain self-management program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 23352229

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (16IU)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 21272822

Group type: EXPERIMENTAL
Intervention: Educational book group
Number of subjects: 167

Group type: COMPARATOR
Intervention: No-book group
Number of subjects: 167

Group type: COMPARATOR
Intervention: Noneducational book group
Number of subjects: 167
Study: 19595446

Group type: EXPERIMENTAL
Intervention: Nano-filled resin-modified GI (nano-RMGI; Ketac N100, 3M-ESPE) without primer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nano-filled resin-modified GI (nano-RMGI; Ketac N100, 3M-ESPE) with primer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional RMGI restorative material (conv-RMGI; Fuji II LC, GC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Packable conventional GI cement (conv-GI; Fuji IX GP, GC)
Number of subjects: 0
Study: 17694478

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15054873

Group type: EXPERIMENTAL
Intervention: High-risk human papillomavirus (hrHPV) testing by GP5+/6+ PCR‐enzyme immunoassay (EIA) in conjunction with cytology
Number of subjects: 44102

Group type: COMPARATOR
Intervention: Classical cytology
Number of subjects: 44102
Study: 11502643

Group type: EXPERIMENTAL
Intervention: 30 mg vesnarinone
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: 60 mg vesnarinone
Number of subjects: 1046

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1046
Study: 9321777

Group type: EXPERIMENTAL
Intervention: Transvaginal sonography
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sonohysterography
Number of subjects: 68

Group type: COMPARATOR
Intervention: Diagnostic hysteroscopy
Number of subjects: 68